

Erythropoietin in Acute Kidney Injury (EAKI): a Pragmatic Randomized Clinical Trial

Mabel Aoun (✉ aounmabel@yahoo.fr)

Saint Joseph University

Ghassan Sleilaty

Saint Joseph University

Celine Boueri

Saint George Hospital

Eliane Younes

Hopital Sacre-Coeur

Kim Gabriel

Serhal Hospital

Reine-Marie Kahwaji

Saint George Hospital

Najla Hilal

Saint George Hospital

Jenny Hawi

Saint George Hospital

Rita Araman

Middle-East Institute of Health

Dania Chelala

Saint Joseph University

Chadia Beaini

Bellevue Medical Center

Research Article

Keywords: Acute kidney injury (AKI), anemia, erythropoietin (EPO), hemoglobin, death, dialysis, randomized pragmatic clinical trial

Posted Date: January 13th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1228530/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Nephrology on March 13th, 2022. See the published version at <https://doi.org/10.1186/s12882-022-02727-5>.

Abstract

Background

Treatment with erythropoietin is well established for anemia in chronic kidney disease patients but not well studied in acute kidney injury.

Methods

This is a multicenter, randomized, pragmatic controlled clinical trial. It included 134 hospitalized patients with anemia defined as hemoglobin <11 g/dL and acute kidney injury defined as an increase of serum creatinine of 0.3 mg/dL within 48 hours or 1.5 times baseline. One arm received recombinant human erythropoietin 4000 UI subcutaneously every other day (intervention; n=67) and the second received standard of care (control; n=67) during the hospitalization until discharge or death. The primary outcome was the need for transfusion; secondary outcomes were death, renal recovery, need for dialysis.

Results

There was no statistically significant difference in transfusion need (RR=1.05, 95%CI 0.65,1.68; p=0.855), in renal recovery full or partial (RR=0.96, 95%CI 0.81,1.15; p=0.671), in need for dialysis (RR=11.00, 95%CI 0.62, 195.08; p=0.102) or in death (RR=1.43, 95%CI 0.58,3.53; p=0.440) between the erythropoietin and the control group.

Conclusions

Erythropoietin treatment had no impact on transfusions, renal recovery or mortality in acute kidney injury patients with anemia.

The trial was registered on ClinicalTrials.gov (NCT03401710, 17/01/2018).

Background

At the beginning of the 90s, following the release of the recombinant human erythropoietin (rhuEPO), transfusions' needs to treat anemia in chronic kidney disease patients were minimized [1]. This has been a revolutionary step in the management of renal anemia in chronic kidney disease and led to a major decrease in hepatitis B and C transmissions in dialysis [2]. However, using erythropoietin (EPO) to treat anemia in acute kidney injury (AKI) remains controversial.

AKI is a common disease with a global incidence estimated at 21% and tends to occur more frequently in the critical care setting [3]. The RIFLE and AKIN criteria for AKI definition were merged by the Kidney Disease Improving Global Outcomes (KDIGO) work group. AKI is defined as an increase in serum creatinine (SCr) ≥ 0.3 mg/dL (≥ 26.5 $\mu\text{mol/L}$) within 48 h or an increase in SCr to ≥ 1.5 times baseline within the last 7 days or a urine volume of <0.5 mL/kg/h for 6 hours [4]. Hales et al reported that the

majority of patients admitted with AKI have anemia (91%) [5]. The presence of anemia in their study was related to the oliguria and uremia level [5]. EPO is secreted by the tubulo-interstitial renal cells and it has been demonstrated that a chronic kidney injury would lead to a decrease in EPO secretion [6]. Some experiments have shown that EPO level usually increases within the first 48 hours of AKI then drops progressively [7]. Transfusions will be needed if critically ill patients are hospitalized for a long period of time [8]. Transfusions may lead to sensitization and can hinder future transplantation in patients who reach end-stage renal disease. Therefore, it is essential to prevent transfusions in AKI patients.

We searched the literature for “recombinant human erythropoietin” or “erythropoietin” and “acute kidney disease” “acute renal failure” or “acute kidney injury”. The search did not reveal any clinical trial assessing rHuEPO use in AKI. Throughout this paper, for a simplification purpose, we will use the term erythropoietin (EPO) instead of the recombinant human erythropoietin (rHuEPO). Based on the literature, some studies assessed the role of EPO before AKI occurrence to prevent kidney injury in cardiac surgery patients and contrast-induced nephropathy with conflicting results [9–14]. Some experimental studies demonstrated a favorable effect of EPO and darbepoetin on the ischemic renal injury in rats [15, 16]. A metaanalysis of 10 randomized controlled trials where the majority of patients received a single dose of EPO concluded that EPO does not prevent AKI or dialysis or death [17]. Two recent clinical trials using high doses of EPO of 40000 UI weekly following cardiac arrest and traumatic brain injury did not show any prevention of AKI and thus no protective renal effect [18, 19].

The role of EPO after the occurrence of AKI is not well studied. In 2005, a retrospective study showed that EPO treatment in acute renal failure patients did not lower the transfusion requirements, the renal recovery or patient survival [20]. However, it included many limitations such as the low dose of EPO used and the retrospective design [20, 21]. A recent clinical trial of children with hemolytic uremic syndrome showed a decrease in transfusion in patients receiving EPO but it included only 10 children [22]. Therefore, a clinical trial that studies the effect of EPO treatment in AKI patients with anemia is needed.

The primary objective of this randomized clinical trial was to compare the need of red blood cell transfusions in patients with AKI and anemia whether receiving or not rHuEPO. The secondary objectives were to compare the renal survival, the need for dialysis and patient death between the two groups.

Methods

Trial design

This was a randomized, controlled, multicenter, pragmatic clinical trial. Patients were randomly assigned in a 1:1 ratio to one of two groups. The intervention group received the EPO treatment and the control group received standard care without EPO. This study aimed to assess the superiority of EPO use in acute kidney injury with anemia against no use of EPO.

Participants and eligibility criteria

Patients included in this trial were admitted to one of the five hospitals where the investigators of this study were practicing: Saint-George Ajaltoun Hospital, Bellevue Medical Center, Serhal Hospital, Sacre-Coeur Hospital, Middle-East Institute of Health.

All adult patients > 18 years old hospitalized with acute kidney injury and anemia were eligible. Acute kidney injury was defined based on the RIFLE, AKIN and KDIGO criteria, as an increase of serum creatinine of 0.3 mg/dL within 48 hours or 1.5 times the baseline level. Anemia was defined in this trial as requiring erythropoietin if Hb <11 g/dl. Since the decrease in hemoglobin levels can be very rapid in acute settings due mainly to inflammatory causes and since the onset of action of erythropoietin takes several days, we started erythropoietin before the patient reaches lower levels of hemoglobin.

Eligible patients were included after giving their informed consent to participate.

Exclusion criteria were: pregnant women, terminally ill patients, active bleeding, patients with major or minor thalassemia, patients on dialysis and patients who were receiving rHuEPO or any erythropoiesis-stimulating agent (ESA) before admission.

Data collection

Data for presumed cause of acute kidney injury, comorbidities, medications and laboratory results were collected from the patients' medical records. The following variables were studied: age, gender, home altitude, body mass index (BMI), diabetes, current smoking status, hypertension, hyperlipidemia, previous cardiovascular disease, chronic inflammatory disease, previous chronic obstructive pulmonary disease (COPD), baseline serum creatinine (Scr) if available (with corresponding estimated glomerular filtration rate (eGFR) using the CKD-EPI equation), Scr, hemoglobin level and C-Reactive Protein (CRP) at the time of AKI diagnosis (T1) and before discharge or death (T2). We collected as well serum phosphate, calcium, albumin, bicarbonate, white blood cells, platelets, ferritin, transferrin saturation (TSAT), LDH, vitamin B12, folic acid, reticulocyte count, uric acid and CPK. Data on previous medications intake were collected: iron, non-steroidal anti-inflammatory drugs (NSAIDs), antihypertensive medications specifically renin-angiotensin-aldosterone system inhibitors (RAASi) such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), antiplatelet and anticoagulant agents, urate lowering therapy, antibiotics, immunosuppressive treatment and corticosteroids. Medications administered during the hospitalization were collected particularly vasopressors such as noradrenaline, dopamine, furosemide, antibiotics, anticoagulants, vitamins, enteral or parenteral nutrition and proton-pump inhibitors. Data including average hospital length of stay (LOS), oligo-anuria at any stage of the AKI, need for dialysis and number of days till renal recovery were collected. Adverse events were also noted such as any thrombotic event.

Ethical considerations

The study got the approval from the ethics committee of Saint-Joseph University number CE-HDF1115 and is in agreement with the Helsinki Declaration of 1975. The patients signed an informed consent before entering the trial. The trial is registered on ClinicalTrials.gov (NCT03401710, 17/01/2018).

Informed consent was signed by the patient or a member of his family. Each participant was assigned two numbers, one for the unit and another for each individual. The data analyst was blinded regarding group allocation.

Interventions

Patients were randomly assigned to one of two groups: Group 1 received erythropoietin (EPO) at least 150 UI/Kg/week subcutaneously divided into three doses per week and EPO treatment was stopped if Hb reached 12 g/dl and above. Group 2 received the usual treatment. Treatment was started within 24 hours of the diagnosis of concomitant AKI and anemia.

Outcomes

Primary outcome:

Need for red blood cell transfusion during the hospitalisation.

Secondary outcomes:

-Renal recovery whether full recovery defined as a decrease of serum creatinine at discharge to the patient's baseline or to less than 1.5 mg/dl or partial recovery defined by any reduction in serum creatinine at discharge.

-Need for dialysis.

-All-cause mortality.

Sample size calculation

If we consider a two-sided alpha of 5% and power of 80% and an effect size = 0.4 (Cohen's effect size, i.e., standardized mean), the total sample size needed would be 198 patients, 99 patients in each arm.

Randomization

Patients were assigned to receive EPO or not, using a 1:1 allocation ratio. We used the randomization plan from the www.randomization.com to generate the random allocation sequence. Each time one of the investigators enrolled a new participant, the others were informed. Being a pragmatic trial, the investigators and patients were not blinded to treatment.

Pragmatic trial: After randomization, the investigators were free to treat and manage the patient based on their usual real-world practice.

Participant timeline

Every patient was followed from first day of acute kidney injury until discharge or transfer or death.

Statistical analysis

Continuous variables are presented as mean \pm standard deviation (SD) if normally distributed and as median and interquartile range (IQR) if skewed. Categorical variables are reported as numbers and percentages. Differences between the two groups of the trial were compared using Chi Square test for categorical variables and Mann-Whitney or t independent test for continuous variables. The risk ratio was calculated for each outcome with the confidence interval (CI). A categorical regression analysis was performed to assess the factors associated with each outcome in the two groups of the trial. Statistical analysis was performed using the Statistical Package for the Social Sciences (IBM SPSS, version 24). A P-value of <0.05 was considered statistically significant.

As of 25/08/2021, a total of 134 patients had been recruited into the study, accounting for 68% of the planned sample size. No further patients could be recruited for several months due to Covid-19 outbreak and the disruption of the usual management of the patients. A decision was reached by the PI, the investigators, the statistician and the ethics committee to terminate prematurely the trial, given the forced zeroing of recruitment rate and the quasi-impossibility of reaching the planned sample size within a reasonable time.

A post-hoc power analysis was performed for the primary outcome for transparency purposes, calculating the power to detect the initially planned effect size of 0.4 with the effective sample size (ref: The 20% Statistician: Observed power, and what to do if your editor asks for post-hoc power analyses (daniellakens.blogspot.com)). Power analysis was performed using GPower software v3.192 (ref: Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behavior Research Methods*, 39, 175-191).

Results

Participant flow

One hundred and thirty-four patients were randomly assigned to receive either erythropoietin (n=67) or standard of care (n=67). No patient was lost or excluded after randomization (Figure 1).

Recruitment

The trial was terminated before reaching the planned sample of 198 patients because of slow recruitment. During the peak of the coronavirus disease (COVID-19) pandemic, no patients were included.

Baseline data

Demographics and baseline clinical and biological characteristics of both groups are listed in Table 1.

Table 1
 Characteristics for AKI patients treated with EPO vs no EPO treatment

	Patients without EPO n=67	Patients treated with EPO n=67	<i>P-value</i>
Age, mean ±SD	78.82 ±12.04	76.42 ±12.98	0.269*
Median (IQR)	81 (73, 86)	79 (69, 86)	
Gender M/F, n(%)	34/33 (50.7/49.3)	37/30 (55.2/44.8)	0.604**
BMI, median (IQR)	27.26 (23.79, 30.79)	26.12 (24.40, 30.66)	0.723***
Diabetes, n(%)	33 (49.3)	37 (55.2)	0.489**
Smoking status, n(%)	12 (17.9)	27 (40.3)	0.005**
Hypertension, n(%)	63 (94.0)	60 (89.6)	0.531****
Hyperlipidemia, n(%)	44 (65.7)	50 (74.6)	0.257**
Previous CVD, n(%)	35 (52.2)	40 (59.7)	0.384**
COPD, n(%)	11 (16.4)	20 (29.9)	0.072**
Chronic inflammation, n(%)	20 (29.9)	19 (28.4)	0.849**
RAASi intake, n(%)	28 (41.8)	26 (38.8)	0.723**
Home altitude in meters, mean ±SD	615.44 ±405.89	623.56 ±356.98	0.916*
Presumed cause of AKI			
o ATN/Sepsis	18 (26.9)	20 (29.9)	
o ATN/Hypovolemia	13 (19.4)	5 (7.5)	0.066**
o ATN/nephrotoxic agents	4 (6.0)	2 (3.0)	
o Cardiorenal	10 (14.9)	15 (22.4)	
o Other	22 (32.8)	25 (37.3)	
Baseline eGFR, mean ±SD	53.86 ±21.82	50.52 ±25.75	0.423*
Baseline eGFR< 60 mL/min, n(%)	41 (61.2)	44 (65.7)	0.591**
Serum creatinine T1, median (IQR)	2.3 (1.7, 4.2)	2.6 (2, 4.4)	0.224***
Hemoglobin T1, median (IQR)	9.7 (8.8, 10.5)	9.4 (8.4, 10.0)	0.034***

*Note. T1, at time of AKI diagnosis; T2, before discharge or death; *t independent test; **Chi-Square; ***Mann-Whitney U test; ****Fischer's Exact test*

	Patients without EPO n=67	Patients treated with EPO n=67	<i>P-value</i>
Serum albumin T1, median (IQR)	32.0 (28.8, 36.0)	31.0 (27.0, 35.0)	0.360***
Serum calcium T1, median (IQR)	8.8 (8.3, 9.1)	8.8 (7.8, 9.2)	0.554***
Serum phosphate T1, median (IQR)	4.2 (3.4, 5.6)	4.6 (3.9, 6.3)	0.077***
Serum bicarbonate T1, median (IQR)	22.0 (19.0, 25.0)	21.0 (18.0, 24.0)	0.337***
Ferritin, median (IQR)	181.75 (61.63, 366.25)	247.0 (99.75, 368.27)	0.564***
TSAT, median (IQR)	12.5 (8.0, 24.3)	10.5 (7.3, 17.4)	0.222***
CRP level T1, median (IQR)	74.0 (12.0, 168.0)	59.85 (20.8, 148.25)	0.752***
Vitamin B12, median (IQR)	322.0 (201.5, 809.5)	347.5 (226.0, 756.75)	0.705***
Folic acid, median (IQR)	10.5 (6.6, 20.0)	7.9 (5.9, 12.3)	0.163***
LDH, median (IQR)	186.5 (164.0, 248.0)	214.5 (174.75, 273.5)	0.088***
Vasopressor use, n(%)	4 (6)	14 (20.9)	0.021****
Corticosteroid use, n(%)	21 (31.3)	23 (34.3)	0.666**
Anticoagulation, n(%)	37 (55.2)	41 (61.2)	0.419**
Oligoanuria, n(%)	11 (16.4)	18 (26.9)	0.142**
Total dose of EPO UI/Kg, median (IQR)	0	150 (88.5, 220.5)	<0.001
Serum creatinine T2, median (IQR)	1.4 (1.1, 2.5)	1.8 (1.2, 2.91)	0.167***
Hemoglobin T2, median (IQR)	9.95 (9.1, 10.6)	9.7 (9.0, 10.5)	0.492***
CRP level T2, median (IQR)	30.0 (14.0, 72.0)	24.5 (12.5, 52.75)	0.381***
Length of stay in days, median (IQR)	8 (6, 13)	9 (6, 14)	0.342***
Number of units of packed red blood cells transfused, median (IQR)	0 (0,2)	0 (0, 1.5)	0.991***
<i>Note. T1, at time of AKI diagnosis; T2, before discharge or death; *t independent test; **Chi-Square; ***Mann-Whitney U test; ****Fischer's Exact test</i>			

Outcomes

There was no statistically significant difference in transfusion need (RR=1.05, 95%CI 0.65,1.68; p=0.855), in renal recovery full or partial (RR=0.96, 95%CI 0.81,1.15; p=0.671), in need for dialysis (RR=11.00, 95%CI 0.62, 195.08; p=0.102) or in death (RR=1.43, 95%CI 0.58,3.53; p=0.440) between the EPO and the control group (Table 2).

Table 2
Clinical Outcomes for EPO treatment vs no EPO treatment in AKI patients

	Patients without EPO n=67	Patients treated with EPO n=67	Risk Ratio	95%Confidence Interval	P- value
Primary outcome, n(%)					
Transfusions	22 (32.8)	23 (34.3)	1.05	0.65, 1.68	0.855
Secondary outcomes, n(%)					
Renal recovery to baseline, full or partial	54 (80.6)	52 (77.6)	0.96	0.81, 1.15	0.671
Dialysis	0 (0)	5 (7.5)	11.00	0.62, 195.08	0.102
Death	7 (10.4)	10 (14.9)	1.43	0.58, 3.53	0.440

Post-hoc power determination for detecting the initial effect size of 0.4 yielded $1 - \beta = 52\%$.

Ancillary analyses

A regression analysis of factors associated with the primary (Table 3) and secondary outcomes (Tables 4 and 5) showed hemoglobin at time of diagnosis of AKI (T1) as significantly associated with need for transfusion in both arms.

Table 3
Factors associated with transfusions in both arms

	Group without EPO			Group with EPO		
	HR	95%CI	p-value	HR	95%CI	p-value
Age	1.03	0.98,1.09	0.250	1.01	0.97,1.05	0.599
Gender	0.73	0.26,2.03	0.545	1.42	0.51,3.96	0.502
Ref: Male						
Baseline eGFR	0.99	0.97,1.02	0.722	0.99	0.97,1.01	0.331
Hemoglobin T1	0.26	0.13,0.51	<0.001	0.35	0.19,0.65	0.001
Platelets' count	1.00	1.00, 1.00	0.476	1.00	1.00, 1.00	0.055
Serum creatinine T1	1.01	0.84,1.19	0.958	1.21	0.99,1.46	0.058
CRP T1	1.00	0.99,1.01	0.444	1.00	0.99,1.01	0.490
Ferritin	1.00	0.99,1.00	0.278	1.04	0.99,1.00	0.198
Anticoagulation	2.24	0.77,6.54	0.140	3.13	0.98,9.97	0.053
Smoking	4.00	1.09,14.66	0.036	0.70	0.25,1.99	0.507
NSAIDs prior use	1.37	0.21,8.84	0.743	1.91	0.11,32.01	0.653
Corticosteroid use	3.40	1.14,10.15	0.028	1.29	0.45,3.69	0.641
<i>Note. HR, hazard ratio; 95%CI, 95% Confidence Interval</i>						

Table 4
Factors associated with death in both arms

	Group without EPO			Group with EPO		
	HR	95%CI	p-value	HR	95%CI	p-value
Age	1.03	0.95,1.13	0.475	1.04	0.98,1.12	0.220
Gender	0.75	0.15,3.64	0.721	3.45	0.81,14.74	0.095
Ref: Male						
Previous CVD	0.66	0.14,3.19	0.601	1.02	0.26,3.99	0.983
Diabetes	1.43	0.29,6.92	0.660	2.10	0.49,8.94	0.316
Baseline eGFR	0.99	0.96,1.04	0.970	1.01	0.99,1.04	0.361
Hemoglobin T1	0.53	0.29,0.94	0.030	0.73	0.39,1.35	0.321
Serum creatinine T1	1.17	0.96,1.43	0.128	0.93	0.69,1.24	0.631
Serum albumin	0.91	0.81,1.02	0.113	0.92	0.83,1.02	0.109
Serum phosphate	1.77	1.19,2.62	0.005	1.17	0.92,1.48	0.206
Serum bicarbonate	0.86	0.74,0.98	0.027	1.05	0.93,1.19	0.425
CRP T1	1.00	0.99,1.01	0.545	1.00	0.99,1.01	0.905
CRP T2	1.01	1.00,1.03	0.034	1.02	1.00,1.03	0.019
Transfusions	6.32	1.12,35.79	0.037	3.53	0.88,14.12	0.075
Full or partial renal recovery	0.13	0.03,0.69	0.017	0.01	0.001,0.12	<0.001
Corticosteroid use	1.71	0.35,8.43	0.511	4.59	1.03,20.53	0.046
Vasopressor use	11.00	1.26,95.69	0.030	9.00	2.07,39.14	0.003
<i>Note. HR, hazard ratio; 95%CI, 95% Confidence Interval</i>						

Table 5
Factors associated with renal recovery in both arms

	Group without EPO			Group with EPO		
	HR	95%CI	p-value	HR	95%CI	p-value
Age	1.04	0.99,1.09	0.139	1.02	0.98,1.06	0.426
Gender	1.72	0.49,5.94	0.389	0.45	0.14,1.46	0.184
Ref: Male						
Diabetes	0.79	0.24,2.68	0.713	0.78	0.24,2.50	0.673
Baseline eGFR	1.00	0.98,1.03	0.821	0.99	0.97,1.01	0.464
Hemoglobin T1	1.19	0.75,1.89	0.470	1.56	0.91,2.68	0.109
Serum creatinine T1	0.96	0.79,1.15	0.641	0.94	0.77,1.16	0.579
CRP T1	1.01	1.001,1.02	0.039	1.01	0.99,1.02	0.134
Serum phosphate	0.79	0.59,1.06	0.120	0.78	0.62,0.99	0.044

Harms

No side-effects of the treatment were noted, specifically thromboembolic events.

Discussion

This is the first randomized clinical trial that assesses the role of erythropoietin treatment in hospitalized patients with acute kidney injury and anemia. It showed no benefit on the transfusion need or renal recovery or patient survival. This is aligned with the results of the retrospective study of Park et al in 2005 that evaluated 187 patients including 71 patients who were administered erythropoietin three times weekly at a mean dose of 112 U/kg/week [20]. It was assumed that the retrospective design of that study and the low dose of erythropoietin prevented from showing any positive effect of erythropoietin on reducing transfusions in acute kidney injury patients. However, in our trial, erythropoietin was given at a median dose of 150 UI/kg for a median of 8-9 days and still was not beneficial. It remains however unknown whether much higher doses can protect patients from being transfused. A recent study on mice showed a U-shaped effect of EPO receptors on renal prognosis following acute kidney injury [23]. Another question that is worth studying in the future is whether concomitant iron administration could help maintain the hemoglobin level at acceptable ranges. Our patients had features of functional iron deficiency. In chronic kidney disease patients, functional iron deficiency is defined as TSAT levels < 20% and ferritin levels higher than 100 ng/mL [24]. These patients might benefit from intravenous iron. This

was not included in the intervention and iron administration was left to the best practice of each physician.

An interesting finding in our study is the association of low hemoglobin levels at time of AKI diagnosis and the need for transfusion with the death outcome. This association was statistically significant in patients who did not receive erythropoietin. Anemia has been associated with mortality in chronic kidney disease patients [25]. The combination of anemia and acute kidney injury was demonstrated as associated with increased mortality in several populations such as patients undergoing coronary artery bypass grafting surgery or patients with chronic heart failure [26, 27]. However, this association is not consistent in all studies and a retrospective cohort of 211 patients in 2013 did not find anemia as affecting the renal or the patient survival [28].

The C-Reactive protein level before death or discharge, the lack of renal recovery and the use of vasopressors were the most significantly associated factors with mortality in our AKI patients. Indeed, a lack of response to treatment, persistent inflammatory markers and hemodynamic instability in septic patients with AKI are the most prominent prognostic factors. This is in alignment with previous studies from different countries [29, 30]. A systematic review in 2013 of 154 large studies that evaluated the world incidence of AKI and associated mortality demonstrated a pooled AKI-associated mortality rates of 23.9% and that rate was declining over time [31]. The low rate of mortality in our group of patients not exceeding 15% can be due to the early diagnosis and management of AKI in this clinical trial setting.

Limitations

Our trial has several strengths and limitations. It is the first clinical trial to study the effect of erythropoietin in patients with anemia and acute kidney injury. It is a multicenter randomized trial and the pragmatic design reflects better the effect of this treatment in the real-world practice [32].

The major limitation is the power and the recruitment of 68% of the desired sample.

In conclusion, this pragmatic trial showed that erythropoietin treatment had no impact on transfusions' need, renal recovery or mortality in acute kidney injury patients with anemia.

List Of Abbreviations

rhEPO, recombinant human erythropoietin; **EPO**, erythropoietin; **AKI**, acute kidney injury; **KDIGO**, Kidney Disease Improving Global Outcomes; **eGFR**, estimated glomerular filtration rate; **CRP**, C-reactive protein; **TSAT**, transferrin saturation; **COPD**, chronic obstructive pulmonary disease; **CVD**, cardiovascular disease; **RAASi**, renin-angiotensin-aldosterone system inhibitors; **ACE**, angiotensin-converting enzyme; **ARBs**, angiotensin receptor blockers; **LOS**, length of stay.

Declarations

- **Ethics approval and consent to participate**

The study got the approval from the ethics committee of Saint-Joseph University number CE-HDF1115 and is in agreement with the Helsinki Declaration of 1975. The patients signed an informed consent before entering the trial. The trial is registered on ClinicalTrials.gov (**NCT03401710, 17/01/2018**).

- **Consent for publication**

Not applicable

- **Availability of data and materials**

All data generated or analysed during this study are included in this published article [and its supplementary information files]

- **Competing interests**

The authors declare that they have no competing interests

- **Funding**

None

- **Authors' contributions**

Research idea: M.A.; Study design: M.A., G.S., DC, Ch.B.; Data acquisition: M.A., Ce.B., E.Y., K.G., RM.K., N.H., R.A., J.H., Ch.B.; Statistical analysis: M.A., G.S.; Data interpretation: M.A., G.S.; Supervision: M.A.; First draft: M.A. All authors reviewed the manuscript.

- **Acknowledgements**

We acknowledge all patients who took part in this study and all colleagues and nurses who contributed to the recruitment of patients.

References

1. Eschbach JW, Abdulhadi MH, Browne JK. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. *Ann Intern Med.* 1989;111(12):992-1000.
2. Bernieh B. Viral hepatitis in hemodialysis: An update. *J Transl Int Med.* 2015;3(3):93-105.
3. Susantitaphong P, Cruz DN, Cerda J, et al. World incidence of AKI: a meta-analysis. *Clin J Am Soc Nephrol.* 2013;8:1482–93.
4. José António Lopes, Sofia Jorge; The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review, *Clinical Kidney Journal.* 2013;6(1):8–14.

5. Hales M1, Solez K, Kjellstrand C. The anemia of acute renal failure: association with oliguria and elevated blood urea. *Ren Fail.* 1994;16(1):125-31.
6. Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, Doe BG, Ferguson DJ, Johnson MH, Ratcliffe PJ. Identification of the renal erythropoietin-producing cells using transgenic mice. *Kidney Int.* 1993;44:1149–1162.
7. Yamashita T, Noiri E, Hamasaki Y et al. Erythropoietin concentration in acute kidney injury is associated with insulin-like growth factor-binding protein-1. *Nephrology (Carlton).* 2016;21(8):693-9.
8. Chant C, Wilson G, Friedrich JO. Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: a cohort study. *Crit Care.* 2006;10(5):R140.
9. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. *Am J Nephrol.* 2009;30:253–260.
10. Oh SW, Chin HJ, Chae DW, Na KY. Erythropoietin Improves Long-Term Outcomes in Patients with Acute Kidney Injury after Coronary Artery Bypass Grafting. *J Korean Med Sci.* 2012; 27(5): 506–511.
11. Kim JE, Song SW, Kim JY et al. Effect of a Single Bolus of Erythropoietin on Renoprotection in Patients Undergoing Thoracic Aortic Surgery With Moderate Hypothermic Circulatory Arrest. *Ann Thorac Surg.* 2016;101(2):690-6.
12. Shema-Didi L, Kristal B, Eizenberg S et al. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial. *Nephrology (Carlton).* 2016;21(4):295-300.
13. Dardashti A, Ederoth P, Algotsson L et al. Erythropoietin and protection of renal function in cardiac surgery (the EPRICS Trial). *Anesthesiology.* 2014;121(3):582-90.
14. Kim JH, Shim JK, Song JW et al. Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety. *Crit Care.* 2013;17(5):R254.
15. Johnson DW, Pat B, Vesey DA et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. *Kidney Int.* 2006;69(10):1806-13.
16. Hamano Y, Aoki T, Shirai R et al. Low-dose darbepoetin alpha attenuates progression of a mouse model of aristolochic acid nephropathy through early tubular protection. *Nephron Exp Nephrol.* 2010;114(2):e69-81.
17. Zhao C, Lin Z, Luo Q et al. Efficacy and Safety of Erythropoietin to Prevent Acute Kidney Injury in Patients With Critical Illness or Perioperative Care: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *J Cardiovasc Pharmacol.* 2015;65(6):593-600.
18. Guillemet L, Jamme M, Bougouin W, et al. Effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratory *post hoc* analyses from an open-label randomized trial. *Clin Kidney J.* 2019;13(3):413-420. Published 2019 Jun 17. doi:10.1093/ckj/sfz068
19. Skrifvars MB, Moore E, Mårtensson J, et al. Erythropoietin in traumatic brain injury associated acute kidney injury: A randomized controlled trial. *Acta Anaesthesiol Scand.* 2019;63(2):200-207.

doi:10.1111/aas.13244

20. Park J, Gage BF, Vijayan A. Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy. *Am J Kidney Dis.* 2005;46(5):791-8.
21. Kraus E and Rabb H. EPO therapy during acute kidney disease: to use or not to use, that is the question. *Am J Kidney Dis.* 2005; 46(5):967-969.
22. Pape L, Ahlenstiel T, Kreuzer M et al. Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome: a randomized prospective pilot trial. *Pediatr Nephrol.* 2009 May;24(5):1061-4.
23. Shi M, Flores B, Li P, et al. Effects of erythropoietin receptor activity on angiogenesis, tubular injury, and fibrosis in acute kidney injury: a "U-shaped" relationship. *Am J Physiol Renal Physiol.* 2018;314(4):F501-F516. doi:10.1152/ajprenal.00306.2017
24. Gafter-Gvili A, Schechter A, Rozen-Zvi B. *Acta Haematol.* Iron deficiency anemia in chronic kidney disease. 2019;142:44-50.
25. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. *Kidney Int.* 2006 Feb;69(3):560–4.
26. Oprea AD, Del Rio JM, Cooter M, et al. Pre- and postoperative anemia, acute kidney injury, and mortality after coronary artery bypass grafting surgery: a retrospective observational study. *Can J Anaesth.* 2018;65(1):46-59. doi:10.1007/s12630-017-0991-0
27. Zhang W, Wen D, Zou YF, et al. One-year survival and renal function recovery of acute kidney injury patients with chronic heart failure. *Cardiorenal Med.* 2015;5(1):40-47. doi:10.1159/000369834
28. Hu SL, Said FR, Epstein D, Lokeshwari M. The impact of anemia on renal recovery and survival in acute kidney injury. *Clin Nephrol.* 2013;79(3):221-228. doi:10.5414/CN107471
29. Yao KH, Konan SD, Tia WM, Diopoh SP, Moh R, Sanogo S. Outcomes of acute kidney injury in a department of internal medicine in ABIDJAN (cote D'IVOIRE). *Nephrology (Carlton).* 2018;23(7):653-660. doi:10.1111/nep.13064
30. Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive Care Med.* 2015;41(8):1411-1423. doi:10.1007/s00134-015-3934-7
31. Susantitaphong P, Cruz DN, Cerda J, et al. World incidence of AKI: a meta-analysis [published correction appears in *Clin J Am Soc Nephrol.* 2014 Jun 6;9(6):1148]. *Clin J Am Soc Nephrol.* 2013;8(9):1482-1493. doi:10.2215/CJN.00710113
32. Ford I, Norrie J. Pragmatic Trials. *N Engl J Med.* 2016;375(5):454-463. doi:10.1056/NEJMra1510059

Figures

CONSORT Flow Diagram




Figure 1

CONSORT flow diagram